Liquid Biopsy Market to Grow at 12.41% CAGR through 2029
Growing
prevalence of cancer and technological advancements in cancer diagnostics is
expected to drive the Global Liquid Biopsy Market growth in the forecast
period, 2025-2029.
According to
TechSci Research report, “Liquid Biopsy Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2019-2029F”, the
Global Liquid Biopsy Market stood at USD
4.38 Billion in 2023 and is anticipated to project steady growth in
the forecast period with a CAGR of 12.41%
through 2029.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Liquid Biopsy Market”
Global
Liquid Biopsy Market presents a dynamic and rapidly evolving landscape shaped
by various factors, including technological advancements, shifting healthcare
paradigms, and increasing demand for non-invasive diagnostic solutions. Liquid
biopsy, a revolutionary approach to disease detection and monitoring, involves
the analysis of biomarkers, such as circulating tumor DNA (ctDNA) and
circulating tumor cells (CTCs), present in biofluids like blood, urine, and
cerebrospinal fluid. This minimally invasive technique offers several
advantages over traditional tissue biopsies, including real-time monitoring of
disease progression, early detection of cancer recurrence, and personalized
treatment selection based on molecular profiling.
One of the
primary drivers fueling the growth of the Global Liquid Biopsy Market is the
rising incidence of cancer and other chronic diseases worldwide. Cancer remains
one of the leading causes of morbidity and mortality globally, driving the
demand for advanced diagnostic tools capable of detecting cancer at an early
stage when treatment is most effective. Liquid biopsy addresses this need by
enabling the detection of molecular alterations associated with cancer,
facilitating early diagnosis, and guiding personalized treatment strategies.
Moreover, liquid
biopsy holds immense potential in revolutionizing cancer management across
various stages of the disease continuum. In addition to early detection, liquid
biopsy assays can monitor treatment response, detect minimal residual disease
(MRD), assess tumor heterogeneity, and identify emerging drug resistance
mechanisms. These capabilities offer valuable insights for oncologists and
patients, enabling informed treatment decisions, optimizing therapy regimens,
and improving patient outcomes.
Technological
advancements play a pivotal role in driving innovation and expansion in the
Global Liquid Biopsy Market. Next-generation sequencing (NGS) technologies, in
particular, have revolutionized liquid biopsy workflows, allowing for
high-throughput analysis of circulating biomarkers with unprecedented
sensitivity and specificity. Additionally, advancements in digital PCR (dPCR),
microfluidics, and bioinformatics have further enhanced the performance and
utility of liquid biopsy assays, enabling the detection of rare mutations and
the characterization of complex genomic alterations.
The increasing
adoption of liquid biopsy in clinical practice is supported by favorable
reimbursement policies and regulatory initiatives aimed at accelerating the
approval and commercialization of liquid biopsy assays. Regulatory agencies
worldwide are recognizing the importance of liquid biopsy technologies in
improving patient care and are streamlining approval processes to expedite
market access. Similarly, reimbursement policies are evolving to cover liquid
biopsy tests, ensuring patient access and affordability, particularly in
developed healthcare markets.
The Global
Liquid Biopsy Market is characterized by a diverse ecosystem of stakeholders,
including biotechnology and pharmaceutical companies, clinical laboratories,
academic research institutions, and healthcare providers. These stakeholders
collaborate to advance the development, validation, and adoption of liquid
biopsy assays across various disease indications, including oncology,
infectious diseases, and prenatal screening. Additionally, strategic
partnerships and collaborations between industry players facilitate technology
transfer, market expansion, and the development of companion diagnostics for
targeted therapies.
Liquid biopsy is
not limited to cancer diagnostics but extends to other disease areas, including
infectious diseases, neurological disorders, and prenatal screening. Liquid
biopsy assays for infectious diseases, such as HIV, hepatitis, and
tuberculosis, offer rapid and sensitive detection methods, enabling timely
intervention and disease management. Similarly, liquid biopsy holds promise in
the early detection and monitoring of neurological disorders, such as
Alzheimer's disease and Parkinson's disease, through the analysis of biomarkers
in cerebrospinal fluid.
Prenatal
screening represents another promising application of liquid biopsy, offering
non-invasive alternatives to traditional invasive procedures like amniocentesis
and chorionic villus sampling (CVS). By analyzing fetal DNA present in maternal
blood, liquid biopsy assays can detect chromosomal abnormalities, such as Down
syndrome, with high accuracy, reducing the risk of miscarriage associated with
invasive procedures and providing expectant parents with valuable genetic
information about their unborn child.
The Global
Liquid Biopsy Market is poised for continued growth and innovation, driven by
ongoing advancements in technology, expanding clinical utility, and increasing
adoption in clinical practice. As liquid biopsy continues to revolutionize
disease diagnostics and management, it holds the potential to transform
healthcare delivery, improve patient outcomes, and pave the way for personalized
medicine tailored to individual patients' molecular profiles.
Global Liquid
Biopsy Market is segmented into offering, technology, workflow, sample,
circulating biomarkers, application, end user, regional distribution, and
company
Based on sample,
blood continues to dominate the Global Liquid Biopsy Market due to its
widespread availability, ease of collection, and rich source of circulating
biomarkers. The comprehensive nature of blood as a sample allows for the
detection of various biomarkers, including circulating tumor DNA (ctDNA),
circulating tumor cells (CTCs), cell-free RNA, and exosomes, providing valuable
information for disease diagnosis, prognosis, and treatment monitoring.
Additionally, blood-based liquid biopsies can be easily integrated into routine
clinical practice, making them highly accessible to healthcare providers and
patients worldwide. As a result, blood remains the preferred sample type in the
liquid biopsy market, driving advancements and innovation in non-invasive
diagnostics.
Based on region,
North America's dominance in the Global Liquid Biopsy Market is underpinned by
its robust healthcare infrastructure, supportive regulatory environment, active
research and development activities, and widespread adoption of personalized
medicine. As the demand for non-invasive diagnostic solutions continues to
grow, North America is expected to maintain its leadership position in driving
innovation and advancements in liquid biopsy technologies. As the demand for
non-invasive diagnostic solutions continues to rise, North America is poised to
maintain its leadership position in driving innovation and advancements in
liquid biopsy technologies. With a strong healthcare infrastructure, supportive
regulatory environment, and active research and development ecosystem, North
America remains at the forefront of shaping the future of liquid biopsy
diagnostics.
Major companies
operating in Global Liquid Biopsy Market are:
- F.
Hoffmann-La Roche Ltd.
- Thermo
Fisher Scientific, Inc.
- PerkinElmer
Inc.
- LungLife
AI, Inc.
- Illumina,
Inc.
- QIAGEN
NV
- NeoGenomics
Laboratories, Inc.
- Myriad
Genetics, Inc.
- Bio-Rad
Laboratories, Inc.
- Guardant
Health Inc.
- Natera,
Inc.
- Sysmex
Corporation
- Abcodia
Ltd.
- Dxcover
Limited
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The future of
the Liquid Biopsy Market appears promising, characterized by substantial growth
and innovation fueled by continual advancements in technology, broadening clinical
applications, and widespread adoption in healthcare facilities worldwide.
Amidst the ongoing evolution of precision medicine, liquid biopsy stands as a
potent non-invasive diagnostic tool, facilitating early disease detection,
treatment monitoring, and personalized therapy selection. By scrutinizing
circulating biomarkers like circulating tumor DNA (ctDNA) and circulating tumor
cells (CTCs), liquid biopsy delivers timely insights into disease progression,
treatment efficacy, and the development of drug resistance. Furthermore, the
integration of artificial intelligence (AI) and machine learning algorithms is
anticipated to bolster the precision and interpretation of liquid biopsy data,
further amplifying its clinical significance and utilization.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Liquid Biopsy Market - Global Industry Size, Share,
Trends, Opportunity, and Forecast, Segmented By Offering (Testing
Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain
Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample
Preparation, Library Preparation, Sequencing, Data Analysis & Management),
By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers
(Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes &
Extracellular Vesicles), By Application (Oncological and Non-oncological), By
End User (Clinical Laboratories, Academic & Research Institutes,
Pharmaceutical & Biotechnology Companies), By Region and Competition, 2019-2029F”,
has evaluated the future growth potential of Global Liquid Biopsy Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Liquid Biopsy Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com